Related Experiment Videos
Advances in antithrombotic therapy: novel agents
A G Turpie1, J I Weitz, J Hirsh
1McMaster University, Hamilton, Ontario, Canada.
Insights
Direct thrombin inhibitors show promise for acute coronary syndromes and deep vein thrombosis prevention. Further dose-finding studies are crucial for safe and effective use in clinical trials.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Direct thrombin inhibitors are increasingly evaluated for cardiovascular conditions.
- Recombinant hirudin shows a narrow safety window with thrombolytics and aspirin in acute myocardial infarction.
Purpose of the Study:
- To review the clinical evaluation and potential of direct thrombin inhibitors.
- To highlight the need for further research into optimal dosing and safety.
Main Methods:
- Review of recent clinical reports and efficacy data.
- Analysis of safety and therapeutic potential in acute coronary syndromes and thrombosis prevention.
Main Results:
- Direct thrombin inhibitors demonstrate efficacy in acute unstable angina and non-Q-wave infarction.
- Recombinant hirudin requires careful safety assessment, especially with combination therapies.
- Potential for deep vein thrombosis prevention in high-risk surgical patients.
Conclusions:
- Direct thrombin inhibitors hold significant potential for managing acute coronary ischaemia.
- Dose-finding studies are essential to establish safe regimens for large-scale clinical trials.
- Further research is needed on novel anticoagulants currently in development.
Abstract:
Most of the clinical evaluation of the direct thrombin inhibitors has been in coronary artery disease. The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction. The efficacy data, however, indicate that the direct thrombin inhibitors have great potential particularly in the initial management of patients with acute unstable angina and non-Q-wave infarction. There is much to learn regarding the mechanism of action, optimal dose, and optimal concomitant therapy in the use of direct thrombin inhibitors in the management of acute coronary ischaemia; and since hirudin and other direct thrombin inhibitors have so much potential in the management of acute coronary ischaemia, it is critical that dose-finding studies be performed to determine safe regimens of these agents to allow their evaluation in large-scale trials with important clinical outcomes. The direct thrombin inhibitors have also shown to have promise in the prevention of deep vein thrombosis in high-risk surgical patients. There is limited clinical data on the other novel anticoagulants which are currently being developed.